Nissan Chemical Corporation · TSE:4021
Nissan Chemical — 2Q FY2026 Earnings Presentation
63 slides from Nissan Chemical's earnings presentation, Nov 9, 2026
Slide 1: Presentation for Investors: 2Q FY2026 Financial Results
November 9, 2026 Presentation for Investors 2Q FY2026 (April 1, 2026 - September 30, 2026) Financial Results Translation of presentation materials for the conference call held on November 9, 2026 Presented by DAIMON Hideki Director, Senior Executive Vice President & CFO
Slide 2: Contents
Contents 01 1H FY2026 Financial Results P3 02 FY2026 Outlook P8 03 Segment Performance P18 04 ESG Topics P45 05 Appendix P50 2
Slide 3: 1H FY2026 Financial Results
Contents 01 1H FY2026 Financial Results P3 3
Slide 4: 1H FY2026 Financial Summary
1H FY2026 Financial Summary ◼ Sales up ¥15.5 billion (+12%) ◼ OP up ¥4.6 billion (+16%) 1H vs. 1H FY2025 ◼ Net Income up ¥3.2 billion (+14%) ◼ Sales, OP and Net Income achieved record-high results ◼ Sales above target ¥14.1 billion vs. 1H Outlook 1H ◼ OP above target ¥5.5 billion as of May 2026 ◼ Ne
Slide 5: 1H FY2026 Financial Summary YOY Change
1H FY2026 Financial Summary YOY Change (¥billion) FY2025 Actual FY2026 Actual YOY Change 1Q 2Q 1H 1Q 2Q 1H 1Q 2Q 1H +15.5 Sales 69.9 60.2 130.1 78.8 66.8 145.6 +8.9 +6.6 (+12%) +4.6 Operating Profit 18.1 11.5 29.6 21.9 12.3 34.2 +3.8 +0.8 (+16%) Non-Operating Income/Expenses 0.0 0.2 0.2 1.7 -1.2 0.5
Slide 6: 1H FY2026 Financial Summary Compared to Outlook
1H FY2026 Financial Summary Compared to Outlook (¥billion) FY2026 Outlook FY2026 Actual vs. Outlook as of May 2026 1Q 2Q 1H 1Q 2Q 1H 1Q 2Q 1H +14.1 Sales 69.1 62.4 131.5 78.8 66.8 145.6 +9.7 +4.4 (+11%) +5.5 Operating Profit 16.8 11.9 28.7 21.9 12.3 34.2 +5.1 +0.4 (+19%) Non-Operating Income/Expense
Slide 7: Analysis of Changes in OP
Analysis of Changes in OP （¥） FY2026 Actual FY2025 Actual YOY Change Outlook as of May 2026 vs. Outlook 34.2billion 29.6billion +4.6 billion（+16%） 28.7billion +5.5billion（+19%） YOY Change +3.5 billion OP increase due to sales increase in Semis Materials and Inorganic Materials Performance Materials
Slide 8: FY2026 Outlook
Contents 02 FY2026 Outlook P8 8
Slide 9: Summary of FY2026 Outlook
Summary of FY2026 Outlook ▍FY2026 Full-Year Outlook OP revised upward to a record high of ¥72.4 billion, from the outlook of ¥66.8 billion announced in May 2026 ◼ Sales up ¥31.5 billion (+11%) Full-Year vs. FY2025 ◼ OP up ¥8.8 billion (+14%), Net Income up ¥3.6 billion (+7%) ◼ EPS Outlook +9%, ROE O
Slide 10: FY2026 Outlook Summary YOY Change
FY2026 Outlook Summary YOY Change (¥billion) FY2026 Outlook FY2025 Actual YOY Change as of Nov 2026 1H 1H 3Q 4Q 2H Total 3Q 4Q 2H Total 1H 3Q 4Q 2H Total Actual +15.5 +5.2 +10.8 +16.0 +31.5 Sales 130.1 65.3 84.2 149.5 279.6 145.6 70.5 95.0 165.5 311.1 (+12%) (+11%) (+11%) +4.6 -0.4 +4.6 +4.2 +8.8 Op
Slide 11: FY2026 Outlook Summary Compared to May 2026
FY2026 Outlook Summary Compared to Outlook as of May 2026 （¥billion） FY2026 Outlook FY2026 Outlook vs. Outlook as of May 2026 as of Nov 2026 as of May 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual +14.1 +7.3 +21.4 Sales 131.5 158.2 289.7 145.6 165.5 311.1 (+11%) (+5%) (+7%) +5.5 +0.1 +5.6 Operatin
Slide 12: Analysis of Changes in OP
Analysis of Changes in OP （¥） FY2026 Outlook FY2025 Actual YOY Change as of Nov 2026 38.2 billion 34.0 billion +4.2 billion（+13%） Performance YOY Change +2.8 billion OP increase due to sales increase in Semis Materials and Display Materials 2H Materials Agrochemicals YOY Change +1.5 billion OP incre
Slide 13: Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Losses YOY Change
Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Losses YOY Change （¥billion） FY2026 Outlook FY2025 Actual YOY Change as of Nov 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual Interest income, dividend income 1.17 0.59 1.76 1.23 0.57 1.80 +0.06 -0.02 +0.04 Equity in earnings of af
Slide 14: Breakdown of Non-Operating Income/Expenses Compared to May 2026
Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Loss Compared to Outlook as of May 2026 （¥billion） FY2026 Outlook FY2026 Outlook vs. Outlook as of May 2026 as of Nov 2026 as of May 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual Interest income, dividend income 1.06 0.63 1.69 1.2
Slide 15: Cash Flows
Cash Flows Free cash flow in FY2026 Outlook is ¥32.4 billion, a decrease of ¥10.6 billion from FY2025 （¥billion） FY2026 Outlook YOY FY2026 FY2025 Actual as of Nov 2026 Change Total Outlook 1H Total 1H Actual Total Total as of May 2026 CF from operating activities 48.7 64.2 54.8 62.5 -1.7 58.0 Income
Slide 16: Balance Sheets
Balance Sheets （¥billion） 2025/9 2026/3 2026/9 vs. 2026/3 2025/9 2026/3 2026/9 vs. 2026/3 Current assets 196.9 222.0 214.6 -7.4 Liabilities 80.9 96.0 88.4 -7.6 Cash 34.3 35.7 43.0 +7.3 Accounts payable 20.6 22.6 23.9 +1.3 Accounts receivable 73.9 97.2 78.4 -18.8 Borrowings, CP & Bonds 26.1 38.4 24.1
Slide 17: Capex, Depreciation, R&D expenses by Segment
Capex, Depreciation, R&D expenses by Segment Capex and Depreciation increased in recent years due to manufacturing capacity expansion (mainly overseas) in core growth businesses. R&D expenses increased in Performance Materials, especially Semis Materials, and Agrochemicals. （¥billion） Capex1 Depreci
Slide 18: Segment Performance
Contents FY2026 Outlook P8 03 Segment Performance P18 18
Slide 19: Performance Materials Overview
Performance Materials Overview ▍ FY2026 Outlook by Segment (¥billion)1 Sales OP Others Healthcare Others 0.5 22.7 1.4 Healthcare Chemicals 5.8 1.5 Performance Performance Chemicals Materials Materials 45.6 136.8 41.6 311.1 72.4 Agrochemicals Agrochemicals 100.2 27.4 ▍ Performance Materials – Recent
Slide 20: Performance Materials Sales by Subsegment, EBITDA Margin Trend
Performance Materials Sales by Subsegment, EBITDA Margin Trend ◼ Semis Materials: High growth rates (YoY change) have been achieved from FY2024 onward, supported by the recovery of Semis market and our strong position in Asia following the temporary adjustment phase in FY2023 ◼ DP Materials: Have ma
Slide 21: Performance Materials Analysis of Changes in OP
Performance Materials Analysis of Changes in OP ◼ Despite higher fixed cost associated with Semis growth investments and capacity expansion of Inorganic Materials in FY2026, profit is expected to increase, driven by price up and volume growth, particularly for Semis. Fixed cost: -7.2 ▍Analysis of Ch
Slide 22: Growth Outlook for our Semis Materials
Performance Materials Growth Outlook for our Semis Materials (No change from the May 2026 announcement) ◼ Our Semis Materials sales growth rate is expected to be +20% or more (2024-2030 CAGR), exceeding the market growth rate of +10% ◼ Particularly for AI server applications, etc., our sales are exp
Slide 23: Performance Materials Sales Growth Rate of Main Products
Performance Materials Sales Growth Rate of Main Products ◼ Semis Materials: 【1H】 Sales YOY +49%, Sales above target 【Full-Year Outlook】 Sales YOY +37％ ◼ DP Materials: 【1H】 Sales YOY -8％, Sales below target 【Full-Year Outlook】 Sales YOY -2％ ◼ Inorganic Materials: 【1H】 Sales YOY +16%, Sales above targ
Slide 24: Performance Materials FY2026 YOY Change
Performance Materials FY2026 YOY Change (¥billion) FY2025 Actual FY2026 Outlook as of Nov 2026 YOY Change 1H 1H 2H Total 2H Total 1H 2H Total Actual Sales 54.4 59.0 113.4 67.0 69.8 136.8 +12.6 +10.8 +23.4 OP 17.4 17.9 35.3 20.9 20.7 41.6 +3.5 +2.8 +6.3 Semis Materials 【1H】 Sales & OP up 【2H】 Sales &
Slide 25: Performance Materials FY2026 Compared to Outlook
Performance Materials FY2026 Compared to Outlook (¥billion) vs. Outlook FY2026 Outlook as of May 2026 FY2026 Outlook as of Nov 2026 as of May 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual Sales 60.2 65.9 126.1 67.0 69.8 136.8 +6.8 +3.9 +10.7 OP 17.8 20.8 38.6 20.9 20.7 41.6 +3.1 -0.1 +3.0 Semis Ma
Slide 26: Agrochemicals Overview
Agrochemicals Overview ▍ FY2026 Outlook by Segment (¥billion)1 Sales OP Others Others Healthcare 22.7 0.5 Healthcare 1.4 Chemicals 5.8 1.5 Performance Chemicals Materials Performance 45.6 136.8 Materials 311.1 72.4 41.6 Agrochemicals Agrochemicals 100.2 27.4 ▍ Agrochemicals – Recent Financial Perfor
Slide 27: Agrochemicals Sales Growth Rate of Main Products
Agrochemicals Sales Growth Rate of Main Products （before discount） 【1H】 Sales YOY -2％, Sales above target 【Full-Year Outlook】 Sales YOY +4% FY2026 Outlook as of May 2026 FY2026 Outlook as of Nov 2026 Main Products （Agro: in order of FY2025 Types YOY Change YOY Change Sales amount） 1H 2H Total 1H Act
Slide 28: Agrochemicals FY2026 YOY Change
Agrochemicals FY2026 YOY Change （¥billion） FY2025 Actual FY2026 Outlook as of Nov 2026 YOY Change 1H 2H Total 1H Actual 2H Total 1H 2H Total Sales 42.3 53.9 96.2 41.4 58.8 100.2 -0.9 +4.9 +4.0 OP 12.0 14.0 26.0 11.9 15.5 27.4 -0.1 +1.5 +1.4 【1H】 Sales & OP slightly down Sales up (ML and AL: volume d
Slide 29: Agrochemicals FY2026 Compared to Outlook
Agrochemicals FY2026 Compared to Outlook （¥billion） vs. Outlook FY2026 Outlook as of May 2026 FY2026 Outlook as of Nov 2026 as of May 2026 1H 2H Total 1H Actual 2H Total 1H 2H Total Sales 39.2 58.0 97.2 41.4 58.8 100.2 +2.2 +0.8 +3.0 OP 11.1 15.9 27.0 11.9 15.5 27.4 +0.8 -0.4 +0.4 【1H】 Sales & OP ab
Slide 30: Agrochemicals Main Products
Agrochemicals Main Products (No change from the May 2026 announcement) Product Launch Products Application development Notes type 2002 ROUNDUP Herbicide Acquired Acquired domestic business from Monsanto, continuing to grow 2008 LEIMAY Fungicide In-house 2008 STARMITE Insecticide In-house 2009 PULSOR
Slide 31: Agrochemicals Product Portfolio
Agrochemicals Agrochemicals Product Portfolio No.1 in the domestic agrochemicals sales ranking (Oct 2023- Sep 2024) In Agrochemical sales(excluding Fluralaner), domestic sales are higher than export sales. ▍Export ratio of agrochemicals business (FY2025 Actual)1・2 Distribution by Region North/Centra
Slide 32: API of Animal Health Product Fluralaner
Agrochemicals API of Animal Health Product Fluralaner (No change from the May 2026 announcement) ◼ BRAVECTO® series and EXZOLT®, which contain the active pharmaceutical ingredient of Fluralaner invented by Nissan Chemical, are currently available in more than 100 countries. ◼ BRAVECTO® 's greatest f
Slide 33: Sales Trend of Fluralaner
Agrochemicals Sales Trend of Fluralaner ▍Nissan Chemical’s Revenue Consists of Two Factors ・Sales of Fluralaner to MAH1 as API2 of BRAVECTO® and EXZOLT® products ・Running royalties received from MAH ▍FY2025 - FY2026 Quarterly Sales ▍FY2022 - FY2026 Sales Trend (including royalties) (including royalt
Slide 34: Chemicals Overview
Chemicals Overview ▍ FY2026 Outlook by Segment (¥billion)1 Sales OP Others Others Healthcare 0.5 22.7 1.4 Healthcare 5.8 Chemicals Performance 1.5 Performance Chemicals Materials Materials 45.6 136.8 41.6 311.1 72.4 Agrochemicals Agrochemicals 100.2 27.4 ▍ Chemicals – Recent Financial Performance2 4
Slide 35: Chemicals FY2026 YOY Change
Chemicals FY2026 YOY Change （¥billion） FY2026 Outlook FY2025 Actual YOY Change as of Nov 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual Sales 18.8 20.5 39.3 20.6 25.0 45.6 +1.8 +4.5 +6.3 Fine Chemicals 6.8 6.9 13.7 7.8 8.1 15.9 +1.0 +1.2 +2.2 Basic Chemicals 12.0 13.6 25.6 12.8 16.9 29.7 +0.8 +3.3
Slide 36: Chemicals FY2026 Compared to Outlook
Chemicals FY2026 Compared to Outlook （¥billion） FY2026 Outlook FY2026 Outlook vs. Outlook as of May 2026 as of Nov 2026 as of May 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual Sales 19.6 21.8 41.4 20.6 25.0 45.6 +1.0 +3.2 +4.2 Fine Chemicals 6.8 7.2 14.0 7.8 8.1 15.9 +1.0 +0.9 +1.9 Basic Chemicals
Slide 37: Flow Chart of Selected Basic and Fine Chemicals Products
Flow Chart of Selected Basic and Fine Chemicals Chemicals Products (No change from the May 2026 announcement) ◼ Core products are ammonia related products and sulfuric acid related products ◼ FY2025 ammonia domestic production capacity share 11% ◼ Focus on high value-added products, such as high pur
Slide 38: Healthcare Overview
Healthcare Overview ▍ FY2026 Outlook by Segment (¥billion)1 Sales OP Others Healthcare Others 22.7 0.5 Healthcare 1.4 5.8 Chemicals Performance 1.5 Chemicals Materials Performance 45.6 311.1 136.8 Materials 72.4 41.6 Agrochemicals Agrochemicals 100.2 27.4 ▍ Healthcare – Recent Financial Performance2
Slide 39: Healthcare FY2026 YOY Change
Healthcare FY2026 YOY Change （¥billion） FY2025 Actual FY2026 Outlook as of Nov 2026 YOY Change 1H 2H Total 1H Actual 2H Total 1H 2H Total Sales 2.8 2.4 5.2 3.1 2.7 5.8 +0.3 +0.3 +0.6 OP 0.7 0.7 1.4 0.9 0.5 1.4 +0.2 -0.2 0.0 【1H】 Sales up, OP slightly up OP slightly up due to fixed cost & others down
Slide 40: Healthcare FY2026 Compared to Outlook
Healthcare FY2026 Compared to Outlook （¥billion） FY2026 Outlook as of May 2026 FY2026 Outlook as of Nov 2026 vs. Outlook as of May 2026 1H 2H Total 1H Actual 2H Total 1H 2H Total Sales 2.5 3.0 5.5 3.1 2.7 5.8 +0.6 -0.3 +0.3 OP 0.5 0.6 1.1 0.9 0.5 1.4 +0.4 -0.1 +0.3 【1H】 Sales & OP above target OP ab
Slide 41: 1H FY2026 Financial Results YOY Change by Segment
1H FY2026 Financial Results YOY Change by Segment （¥billion） FY2025 Actual FY2026 Actual YOY Change 1Q 2Q 1H 1Q 2Q 1H 1Q 2Q 1H Sales 25.9 28.5 54.4 32.6 34.4 67.0 +6.7 +5.9 +12.6 Performance (+23%) Materials +3.5 OP 8.2 9.2 17.4 10.7 10.2 20.9 +2.5 +1.0 (+20%) Sales 26.6 15.7 42.3 26.6 14.8 41.4 0.0
Slide 42: 1H FY2026 Results Compared to Outlook by Segment
1H FY2026 Financial Results Compared to Outlook by Segment （¥billion） FY2026 Outlook vs. Outlook FY2026 Actual as of May 2026 as of May 2026 1Q 2Q 1H 1Q 2Q 1H 1Q 2Q 1H 32.6 34.4 67.0 +3.0 +3.8 +6.8 Sales 29.6 30.6 60.2 Performance (+11%) Materials +3.1 OP 8.3 9.5 17.8 10.7 10.2 20.9 +2.4 +0.7 (+17%)
Slide 43: FY2026 Financial Outlook YOY Change by Segment
FY2026 Financial Outlook YOY Change by Segment （¥billion） FY2026 Outlook FY2025 Actual YOY Change as of Nov 2026 1H 1H 3Q 4Q 2H Total 3Q 4Q 2H Total 1H 3Q 4Q 2H Total Actual 54.4 67.0 +12.6 +6.3 +4.5 +10.8 +23.4 Sales 28.6 30.4 59.0 113.4 34.9 34.9 69.8 136.8 Performance (+23%) (+18%) (+21%) Materia
Slide 44: FY2026 Financial Outlook Compared to Outlook by Segment
FY2026 Financial Outlook Compared to Outlook by Segment （¥billion） FY2026 Outlook FY2026 Outlook vs. Outlook as of May 2026 as of Nov 2026 as of May 2026 1H 1H 2H Total 2H Total 1H 2H Total Actual +6.8 +3.9 +10.7 Sales 60.2 65.9 126.1 67.0 69.8 136.8 Performance (+11%) (+6%) (+8%) Materials +3.1 -0.
Slide 45: ESG Topics
Contents FY2026 Outlook P8 04 ESG Topics P45 45
Slide 46: ESG
ESG April 2021 Announced its Diversity Statement and Diversity Vision Decided to work on realization of carbon neutrality by 2050 May 2022 Established new long-term target for reducing greenhouse gas (GHG) emissions (see p49) E June 2022 Reduced GHG emissions by melamine production stop (26,000 tons
Slide 47: ESG Index and Third-party Recognition
ESG Index and Third-party Recognition Dow Jones Best-in-Class Asia Pacific Index S&P/JPX Carbon Efficient Index ◼ April 2026 ◼ June 2026 Selected as a constituent for 8 consecutive years, Selected as a constituent including the former Dow Jones Sustainability Asia Pacific Index for 8 consecutive yea
Slide 48: Materiality (Mid-Term Business Plan Vista2027 Stage II)
Materiality (Mid-Term Business Plan ”Vista2027 Stage II”) (No change from the May 2025 announcement) Specified materiality that we should engage to realize corporate image of 2027. Aim to have sustainable growth with society by promoting initiatives. 1 2 3 Provision of New Value for Strengthening of
Slide 49: Reduction of GHG Emissions
Reduction of GHG Emissions ◼ To achieve carbon neutrality by 2050, focus on initiatives such as improving production technology and adopting renewable energy, in addition to conventional efforts ◼ FY2027 GHG emissions target is expected to achieve at least a 30% reduction compared to FY2018 (Scope 1
Slide 50: Appendix
Contents FY2026 Outlook P8 05 Appendix P50 50
Slide 51: Capital Allocation (Mid-Term Business Plan Vista2027 Stage II)
Capital Allocation (Mid-Term Business Plan ”Vista2027 Stage II”) (No change from the May 2025 announcement) ◼ Generating cash steadily ◼ Strategic capital allocation for continuous growth and enhancement of Corporate Value FY2025 - 27 Total （Round number） Allocation Strategies Debt finance for Strat
Slide 52: ROE Trend
ROE Trend ◼ Position ROE as the most important financial indicator for a long time ◼ Medium-Term Plan FY2025-2027 Target: 18% or more ◼ FY2025 Actual: 20.3% (¥billion) Net Income (left axis) ROE (right axis) 80.0 25% 70.0 20.3% 20.3% 19.2% 19.4% 18.7% 20% 60.0 17.5% 17.1% 16.9% 16.1% 16.6% 53.3 49.7
Slide 53: Shareholders Return Policy - Total Payout Ratio
Shareholders Return Policy - Total Payout Ratio ◼ Medium-Term Plan FY2025-2027 Target: 75% or more ◼ FY2025 Actual: 75.7% Share Repurchase Amount (composition of Net Income) (left axis) Total Dividend Amount (composition of Net Income) (left axis) 100% (¥billion) Total Payout Ratio (right axis) 50.0
Slide 54: Shareholders Return Policy – Dividend Payout Ratio
Shareholders Return Policy – Dividend Payout Ratio ◼ Increase Dividend Payout Ratio Target to 55% from 45% in Medium-Term Plan (announced in May 2022) ◼ Current Medium-Term Plan (FY2025-2027) target: 55% or more ◼ Stable and continuous dividend policy ◼ Maintained Dividend at the same amount (¥164/s
Slide 55: Shareholders Return Policy - Share Repurchase
Shareholders Return Policy - Share Repurchase ◼ Started share repurchase in FY2006 only to enhance ROE ◼ Repurchased ¥145.5 billion, 52.28 million shares (27.9% of shares issued) in total from FY2006 to FY2025 ◼ Cancelled all repurchased shares. Continue to strengthen shareholders return through sha
Slide 56: R&D Expenses Trend
R&D Expenses Trend ◼ R&D expenses increased in Performance Materials, especially Semis, and Agrochemicals ◼ Maintain about 7-9% R&D expenses/sales in recent years (¥billion) R&D expenses(left axis) R&D expenses/sales(right axis) 10% 9.2% 8.9% 8.9% 8.9% 8.9% 8.7% 8.7% 8.7% 30.0 8.3% 8.2% 7.9% 7.7% 7.
Slide 57: R&D Investment Philosophy
R&D Investment Philosophy ◼ Achieve high OP margin despite aggressive investment in R&D ◼ About 40% of professional staff engaged in R&D ▍R&D Expenses by Segment FY2025 Actual Sales OP R&D expenses R&D OP Margin (¥billion) (¥billion) (¥billion) Expenses/Sales Performance Materials 113.4 35.3 31.1% 1
Slide 58: Long-term Financial Performance Trend
Long-term Financial Performance Trend (¥billion) 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026E Sales 169.2 160.2 149.0 154.2 148.6 153.8 163.7 171.2 176.9 180.3 193.4 204.9 206.8 209.1 208.0 228.1 226.7 251.4 279.6 311.1 Operating Profit 24.8 17
Slide 59: Sales and OP Trend by Segment
Sales and OP Trend by Segment (¥billion) ▍Sales (A) 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026E Performance Materials 49.4 51.8 52.8 58.8 63.0 65.5 71.6 81.7 82.6 84.6 100.1 113.4 136.8 Agrochemicals 45.7 47.5 52.0 58.1 62.7 64.0 63.8 65.8 81.6 82.1 86.2 96.2 100.2 Chemicals 34
Slide 60: Quarterly Sales Trend by Segment (FY2023 - FY2026 Outlook)
Quarterly Sales Trend by Segment (FY2023 - FY2026 Outlook) (¥billion) FY2026 Outlook FY2026 Outlook FY2023 Actual FY2024 Actual FY2025 Actual as of Nov 2026 as of May 2026 1Q 2Q 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 3Q 4Q Total 1Q 2Q 2H Total Actual Actual Performance Materials 20.8
Slide 61: Quarterly OP Trend by Segment (FY2023 - FY2026 Outlook)
Quarterly OP Trend by Segment (FY2023 - FY2026 Outlook) (¥billion) FY2026 Outlook FY2026 Outlook FY2023 Actual FY2024 Actual FY2025 Actual as of Nov 2026 as of May 2026 1Q 2Q 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 1Q 2Q 3Q 4Q Total 3Q 4Q Total 1Q 2Q 2H Total Actual Actual Performance Materials 6.5 4.6
Slide 62: Main Products by Segment
Main Products by Segment Segment Products Main Applications Performance Semis Materials ® ARC (ArF, KrF) bottom anti-reflective coating for semiconductors Materials Multi-layer process materials for semiconductors OptiStack® (Si-HM: Silicon Hard Mask / SOC: Spin-On Carbon ) EUV materials EUV process
Slide 63: Disclaimer and Copyright
Disclaimer and Copyright The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncerta